Irland - engelska - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - methotrexate - solution for injection in pre-filled injector - 20 milligram(s) - folic acid analogues; methotrexate

Irland - engelska - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - methotrexate - solution for injection in pre-filled injector - 22.5 milligram(s) - folic acid analogues; methotrexate

Irland - engelska - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - methotrexate - solution for injection in pre-filled injector - 25 milligram(s) - folic acid analogues; methotrexate

Irland - engelska - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - methotrexate - solution for injection in pre-filled injector - 27.5 milligram(s) - folic acid analogues; methotrexate

Irland - engelska - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - methotrexate - solution for injection in pre-filled injector - 30 milligram(s) - folic acid analogues; methotrexate

Irland - engelska - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - methotrexate - solution for injection in pre-filled injector - 7.5 milligram(s) - folic acid analogues; methotrexate

Irland - engelska - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - methotrexate - solution for injection in pre-filled syringe - 50 milligram(s)/millilitre - other immunosuppressants; methotrexate

Australien - engelska - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tobramycin, quantity: 40 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; water for injections; sulfuric acid; sodium metabisulfite; disodium edetate - tobramycin is indicated in the treatment of the following serious infections caused by susceptible micro-organisms: central nervous system infections, including meningitis; septicaemia and neonatal sepsis; gastro-intestinal infections, including peritonitis; complicated and recurrent urinary tract infections such as pyelonephritis and cystitis; lower respiratory tract infections, including pneumonia, bronchopneumonia and acute bronchitis; bone, skin and skin structure infections, including burns.,tobramycin may be considered in serious staphylococcal infections for which penicillin or other less potentially toxic drugs are contraindicated and when bacterial susceptibility testing and clinical judgement indicate its use. aminoglycosides, including tobramycin, are not indicated in uncomplicated initial episodes or urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity.,bacterial cultures should be obtained prior to and during treatment to isolate and identify aetiologic organisms and to test their susceptibility to tobramycin. if susceptibility tests show that the causative organism is resistant to tobramycin, other appropriate therapy should be instituted. in patients in whom gram negative septicaemia, neonatal sepsis, or meningitis is suspected, including those in whom concurrent therapy with a penicillin or cefalosporin and an aminoglycoside may be indicated, tobramycin therapy may be initiated before results of susceptibility studies are obtained. the decision to continue tobramycin therapy should be based upon the results of susceptibility studies, severity of the infection, and the important additional concepts discussed in the product information document.

Europeiska unionen - engelska - EMA (European Medicines Agency)

pari pharma gmbh - tobramycin - respiratory tract infections; cystic fibrosis - antibacterials for systemic use, - vantobra is indicated for the management of chronic pulmonary infection due to pseudomonas aeruginosa in patients aged 6 years and older with cystic fibrosis (cf).consideration should be given to official guidance on the appropriate use of antibacterial agents.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tobramycin, quantity: 80 mg - injection, solution - excipient ingredients: water for injections; disodium edetate; sodium hydroxide; sulfuric acid - for the treatment of serious infections of the following type where they are caused by susceptible organisms: skin and skin structure infections including burns, bone infections; gastrointestinal infections including peritonitis; central nervous system infections including meningitis, septicaemia and neonatal sepsis; lower respiratory tract infections including pneumonia, bronchopneumonia, and acute bronchitis; complicated and recurrent urinary tract infections such as pyelonephritis and cystitis.,aminoglycosides, including tobramycin, should not be used in uncomplicated initial episodes of urinary tract infection unless the causative organisms are not susceptible to other less toxic antibiotics.,tobramycin can be used in serious staphylococcal infections for which penicillin or other less toxic drugs are contraindicated and where susceptibility testing and clinical judgement indicate its use. if susceptibility tests show a resistance to tobramycin in the causative organisms other appropriate therapy should